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The epidemiology of chronic kidney disease. The world’s dis-
ease profile is changing, and chronic diseases now account for
the majority of global morbidity and mortality, rather than in-
fectious diseases. The causes of chronic kidney diseases reflect
this change and diabetes, together with hypertension, is now
the major cause of end-stage renal failure worldwide, not only
within the developed world, but also increasingly within the
emerging world.
Diabetes is of epidemic proportions, and its prevalence will
double in the next 25 years, particularly in the developing coun-
tries. This will place an enormous financial burden on countries,
including the cost of the management of end-stage renal failure.
Thus, it is medically and economically imperative for awareness,
detection, and prevention programs to be introduced across the
world, particularly in the developing countries. This will require
concerted action from global institutions, governments, health
service providers, and medical practitioners.
The pattern of disease morbidity and mortality
throughout the world is changing both in the devel-
oped and the emerging world. During the 20th century,
infectious diseases were the major cause of death and
disability. However in this century, noncommunicable,
noninfectious diseases have become the major cause of
mortality and morbidity around the world [1, 2]. This
change is reflected in the type of diseases causing chronic
kidney failure and in their presentation and progression.
Today, the major cause of end-stage renal failure is di-
abetes as a result of the global pandemic of type 2 di-
abetes. The rate of progression is extraordinary, and it
is predicted that there will be a doubling of the num-
ber of patients with type 2 diabetes around the world in
the next 25 years [3]. This will lead to a corresponding
increase in the number of patients with chronic kidney
disease and the number requiring end-stage renal failure
management, particularly dialysis.
This paper examines five epidemiologic aspects of
chronic kidney disease. First, the prevalence of early kid-
ney damage; second, the prevalence and incidence of
end-stage kidney failure; third, the changing patterns of
chronic kidney disease; fourth, the diabetes and cardio-
vascular pandemic; and finally, what can be done to re-
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duce the impending disease burden with all its medical
and financial ramifications.
COMMUNITY PREVALENCE OF EARLY
KIDNEY DISEASE
The prevalence of early kidney disease in the gen-
eral community has been studied little [4, 5]. However,
a recent AUSDIAB study from 1999 to 2000 evaluated
the prevalence of diabetes, metabolic risk factors, and
indicators of renal disease in the broad Australian com-
munity, and the results have provided an increased un-
derstanding of the burden of kidney disease within the
community, and this appears to be applicable worldwide
[6]. The AUSDIAB study was a cross-sectional preva-
lence study and included determining the prevalence of
diabetes mellitus and abnormal glucose metabolism, hy-
pertension, kidney disease, cardiovascular disease, and
lifestyle and health behavior. Adults (11,247) more than
25 years old were screened between April 1999 and
December 2000. Albuminuria was determined by urine
albumin:creatinine ratio with normal ≤3.4 mg/mmol, mi-
croalbuminuria = 3.4 to 34 mg/mmol, and macroalbu-
minuria ≥34 mg/mmol. Proteinuria was determined by
urine to protein:creatinine ratio (mg/mg) with abnormal
proteinuria ≥0.2 mg/mg, which approximates 250 mg/
24-hour excretion. Renal impairment was measured by
the Cockcroft-Gault GFR formula using serum creati-
nine plus body surface area and gender adjustments.
Hematuria was determined initially by a dipstick, and
was followed-up by urine microscopy if a dipstick was
positive for blood. Hypertension was established by his-
tory, treatment, and three sitting blood pressure measure-
ments. Diabetes, impaired fasting glucose, and impaired
glucose intolerance were diagnosed by a fasting glucose
level and a 2-hour oral glucose tolerance test [6].
The AUSDIAB results showed that 7.2% of adult
Australians in the community have diabetes. A portion
(3.6%) knew they had diabetes, and 3.6% were undiag-
nosed. A percentage of adults (16.1%) had impaired glu-
cose metabolism, 60% were overweight or obese, 61%
had high cholesterol, and 29% had elevated blood pres-
sure, with only 14% on treatment.
The AUSDIAB study showed the prevalence of renal
abnormalities in the Australia community was hematuria
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Prevalence of microalbuminuria: Effect
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Fig. 1. The effect of glucose tolerance and
hypertension on the prevalence of microalbu-
minuria.
(5.6%), proteinuria (2.4%), albuminuria (5.3% in males
and 7.1% in females), and renal impairment, defined by
a calculated GFR of less than 60 mL/m, was 12.1%.
This means that 18% of adult Australians had at least
one indicator of chronic kidney disease. This is similar to
the results of NHANES Study in the United States [7].
The effect of hypertension and glucose tolerance on
the prevalence of albuminuria demonstrated an enhanc-
ing effect (Fig. 1). With increasing degrees of glucose in-
tolerance there were increasing amounts of albuminuria.
However, when the effect of hypertension was also taken
into account, microalbuminuria was increased at each de-
gree of glucose intolerance in an incremental fashion,
with 25.4% of people with diabetes mellitus and hyper-
tension having albuminuria. This is in keeping with other
series, but is less than reported in the recent Demand
Project, which showed 49% of 31,470 patients with type
2 diabetes from 34 countries had microalbuminuria as
determined by dipstick analysis [8].
The AUSDIAB study also showed a prevalence of mi-
croalbuminuria of 6.1% in the general population. Of
these, 74% had hypertension either alone (22%) or with
glucose intolerance (41%). Thirteen percent had microal-
buminuria associated with smoking, urinary infection,
hematuria, or renal impairment (GFR <60 mL/m), 13%
had isolated microhematuria (Fig. 2). Fifty-three percent
of people in the community with microalbuminuria had
impaired glucose tolerance. Therefore, of the people test-
ing positive for microalbumunria in the general popula-
tion, approximately half had glucose intolerance, most of
these associated with hypertension. A fourth will be hy-
pertensive alone, and another fourth will have microalbu-
minuria from other causes, including glomerulonephritis.
Thus, on a community basis, microalbumunira is mainly
associated with glucose intolerance and hypertension.
PREVALENCE AND INCIDENCE OF END-STAGE
RENAL FAILURE
Approximately 30% of patients with diabetic
nephropathy eventually progress to end-stage renal
failure, and the rest usually die from cardiovascular
disease before reaching end stage. All develop microal-
buminuria and, subsequently, proteinuria. Therefore,
albuminuria is an important risk factor in these patients,
and all diabetic patients should have a microalbuminuria
assessment yearly [9]. Indeed, albuminuria is strongly
associated with progression of kidney disease, in addition
to prediction of cardiovascular events not only in diabetic
patients, but also in the general community [10, 11].
Thus, the combination of diabetes, hypertension, and
chronic kidney disease is now the most common cause
of end-stage kidney failure worldwide.
The incidence of patients with end-stage renal disease
being treated by renal replacement therapy varies enor-
mously depending on the level of affluence of the country.
The highly developed countries such as North America,
Europe, and Japan have the highest incident rates of
treated end-stage renal failure, whereas the emerging
countries have very low incident rates. There are now over
1 million dialysis patients worldwide, with an incidence of
about a quarter of a million new patients each year. [12]
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in the population ?
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Fig. 2. The significance of microalbuminuria in terms of underlying
disease.
The annual incidence of new cases of end-stage renal fail-
ure in Hong Kong from their renal registry data demon-
strates the worldwide trend of progressively increasing
numbers. In 1996, there were 100 patients/million pop-
ulation beginning dialysis in Hong Kong. In the year
2000, this increased to 122 patients, and in 2003, 140 pa-
tients/million population began treatment for end-stage
renal failure. Similarly, the rates have been increasing in
the United States, and with increasing prevalence, it is
predicted that by 2010, there will be almost 700,000 dial-
ysis patients in the United States, costing about US$30
million a year for their dialysis treatment [13]. Obviously,
treatment of such an ever-increasing burden of end-stage
kidney failure cannot be afforded, even in the wealthiest
of countries.
CHANGING PATTERNS OF CAUSE OF CHRONIC
KIDNEY DISEASE
The major cause of end-stage renal failure in most
countries worldwide is now diabetes. Over the past
decade, the USRDS figures demonstrate a progressive in-
crease in the number of diabetics entering end-stage renal
failure programs. Now, 44% of all incident patients are di-
abetic (www.USRDS.org), while glomerulonephritis, cys-
tic kidney disease, and hypertension have remained rela-
tively steady as causes of end-stage renal failure over the
past decade. This is reflected also in Australia, where the
incidence of end-stage renal failure due to diabetes is 25%
(www.ANZDATA.org.au), and in the European Registry
Data, where the number of diabetics entering end-stage
renal failure programs is now between 15% and 33%,
while the numbers entering due to glomerulonephritis
are 7% to 20% (www.ERA-EDTA-Reg.org/index.55p).
Figures from the Hong Kong Renal Registry also show
a progressive increase in the number of diabetics begin-
ning dialysis, which now represents 38% of the incident
patients, while only 23% were due to glomerulonephri-
tis. Other countries throughout Asia also have large per-
centages of their incident end-stage renal failure patients
due to diabetes: Pakistan, 42%, Taiwan, 35%, Philippines,
25% and Japan, 37% (USRDS 2003).
This inexorable progressive increase can be gauged by
the figures over the past 20 years from the Australian and
New Zealand Dialysis & Transplant Registry. Figure 3
demonstrates the relatively steady acceptance rate of
type 1 diabetes over this time, but the progressive in-
crease in the number of type 2 diabetic patients being
accepted into dialysis programs over the past 2 decades
(Fig. 3). Diabetes is now the major cause of end-stage
renal failure worldwide in both developed and emerging
countries.
THE PANDEMIC OF DIABETES AND
CARDIOVASCULAR DISEASE
The prevalence of type 2 diabetes is rising progressively
around the world. For example, the diabetes prevalence
in Singapore has risen from 2% in 1975 to over 8% in
1998, and this is reflected in many Chinese communi-
ties throughout the world. Predictions for the diabetes
epidemic in China have indicated an increase for the
community prevalence of diabetes from 4% to 10% over
the next 10 years. In 2000, a World Health Organization
survey showed that 5.2% of Chinese men (12.7 million)
and 5.3% of Chinese women (13.3 million) had diabetes.
Three fourths were previously undiagnosed. This repre-
sents an enormous number of people, as China is the most
populous nation in the world. India, the second most pop-
ulous country, has the most diabetics in the world. This is
reflected by an associated high prevalence of cardiovas-
cular disease in India, and coronary deaths are expected
to reach 2 million per year by 2010.
The prevalence of diabetes in the Asian Pacific area is
variable but increasing. In the highlands of Papua New
Guinea, there is virtually zero incidence of type 2 dia-
betes, but on relocation to urban cities in Papua New
Guinea, the prevalence rises to 16%. Nauru, a small is-
land state in the Pacific, has a prevalence of 42% of type
2 diabetes among the adult population. The global pro-
jection by the International Diabetes Federation predicts
that the number of diabetics in the world will rise from
189 million today to 224 million in the year 2025 [3], an in-
crease of 72%. Furthermore, the International Diabetes
Federation has predicted an increase in diabetic numbers
of 88% in South America, 59% in North America, 18%
in Europe, 98% in Africa, 97% in the Middle East, and
91% in Asia over the next quarter of a century. Thus,
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diabetes will drive the future epidemics in cardiovascular
and renal disease. This additional burden of progressive
chronic kidney disease due to the diabetes pandemic will
constitute one of the greatest medical challenges of the
21st century.
In addition, the explosion in the number of people
with diabetes has enormous economic implications. The
cost affects individuals and families, as well as health ser-
vices and also national productivity. Individual families
are greatly affected. Studies from India have estimated
that as much as 25% of the family income may be devoted
to diabetes treatment of an adult. The cost of diabetic
care ranges from 2.5% to 15% of national health care
budgets. The global cost of diabetes is now $150 billion,
and will double by 2025. By then, countries with a high
prevalence of diabetes, such as China and India, may be
spending up to 40% of their health care budget on dia-
betes and its complications. In addition, the cost of death
and disability due to chronic disease is profound, and will
reduce productivity, particularly in the emerging world,
and significantly reduce economic growth.
WHAT CAN BE DONE?
We have a great challenge to communicate the mag-
nitude of the diabetic, cardiovascular, and chronic dis-
ease kidney problem to communities and to governments
worldwide [14]. The International Society of Nephrology
is responding to this challenge by forming partnerships
with other appropriate societies, such as the International
Diabetes Federation, with agencies and foundations such
as the World Health Organization, the World Bank, and
the Rockefeller Institute [15], in order to influence global
and national health policy and decision makers as to
the enormity of this chronic disease problem. It will
also require a concerted approach from individual prac-
titioners, nephrologists, and diabetic and cardiovascular
physicians. Detection and prevention programs, includ-
ing screening of communities for diabetes, hypertension,
and chronic kidney disease have to be implemented in
order to avert this enormous problem of chronic disease.
Lifestyle changes, modification of the ill effects of sweep-
ing globalization, and massive community education will
be needed. This ISN Hong Kong Prevention Congress
is one such initiative to provide a multidisciplinary ap-
proach to the chronic disease problem, particularly within
the Asian Pacific area. However, the discussions and out-
comes are world encompassing.
Reprint requests to Professor Robert C. Atkins, Department of
Nephrology, Monash Medical Centre, 246 Clayton Road, Clayton 3168,
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